CFAR - in relapsed/refractory CLL

[Guest guest]

Study from MD reports the outcome for 80 relapsed

or refractory patients with CLL enrolled in a phase II study

of cyclophosphamide, fludarabine, alemtuzumab (Campath) and

rituximab (CFAR).

The researchers noted higher CR in high-risk patients

following CFAR compared to a similar population who had

received FCR as salvage therapy.

There was no significant improvement in PFS and OS appeared

worse. About 50% of patients experienced a high rate of

infectious complications and 28% experience late serious

infections.

http://www.ncbi.nlm.nih.gov/pubmed/21670470

[Guest guest]

The results suggest to me that we can & should do

better...lethal side effects from potent therapies in

patients with marginal reserves is not the bargain that any

of us would wish to make.